Viking Therapeutics is a clinical-stage biopharmaceutical company developing novel therapies for metabolic and endocrine disorders, with particular focus on liver disease and obesity-related conditions. The company's pipeline includes multiple drug candidates at varying development stages, with lead programs advancing through Phase 2 clinical trials, supported by intellectual property rights acquired from established pharmaceutical partners. Viking is pre-revenue and funds its research and development activities—the primary component of its operating costs—through equity capital raises, expecting no revenue until it obtains regulatory approval for its drug candidates and either commercializes them independently or enters into collaborative agreements with third parties.